FDA warned rx2go.com for selling unapproved, misbranded hydroxychloroquine and other drugs online with COVID-19 claims.
What happened
FDA reviewed www.rx2go.com on January 5, 2021, and found that the website offered drug products for sale in the U.S. with claims to treat, prevent, or cure COVID-19 and other diseases. The letter cites hydroxychloroquine marketed as “hydroxychloroquine sulfate (Generic Plaquenil)” and “Signaquine-200” manufactured by Signature, and says no approved applications are in effect for those products. It also says the site misleadingly described the products as FDA-approved and that hydroxychloroquine is not approved for COVID-19.
What FDA found
Offering unapproved new drugs for sale without FDA approval.
section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]Selling prescription drugs without adequate directions for use, making them misbranded.
section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]Putting unapproved and misbranded drugs into interstate commerce.
sections 301(a) and (d) of the FD&C Act [21 U.S.C. § 331(a) and (d)]Calling the hydroxychloroquine products FDA-approved when FDA has not approved those specific products.
section 502 of the FD&C Act [21 U.S.C. § 352]Claiming hydroxychloroquine can treat or prevent COVID-19 even though FDA has not approved it for that use.
section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]
What FDA wants
Within 48 hours, email FDA describing specific steps taken to address the violations and prevent recurrence, with supporting documents. If the company believes it is not violating the law, it must send its reasoning and supporting information within 48 hours.
Who should pay attention
- consumers who buy prescription drugs from online pharmacies
- online pharmacies and websites selling COVID-19-related drugs
- companies whose products are copied or misrepresented as FDA-approved
This is a summary. Read the original letter on fda.gov.